Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Holding(s) in Company

9 Oct 2025 07:00

RNS Number : 6418C
Tissue Regenix Group PLC
09 October 2025
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Tissue Regenix Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Lombard Odier Asset Management (Europe) Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

07.10.2025

6. Date on which issuer notified (DD/MM/YYYY):

08.10.2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.95%

10.95%

7,819,294

Position of previous notification (if

applicable)

11.12%

11.12%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BNTXR104

7,819,294

10.95%

SUBTOTAL 8. A

7,819,294

10.95%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

08.10.2025

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWUKRVOURRAA
Date   Source Headline
12th Oct 20167:00 amRNSInterim Results
28th Sep 20167:00 amRNSNotice of Interim Results
15th Sep 20163:07 pmRNSEdison issues outlook on Tissue Regenix
1st Sep 20167:00 amRNSDermaPure® Medicare coverage in further 10 States
3rd Aug 20167:15 amRNSHardman & Co Research Report on: Tissue Regenix
28th Jul 201610:58 amRNSEdison research outlook on Tissue Regenix (TRX)
18th Jul 201611:20 amRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
11th Jul 20167:00 amRNSOrthopaedics Update
4th Jul 201610:41 amRNSResult of AGM
1st Jul 20167:00 amRNSDermaPure® secures first GPO contract in US
30th Jun 20167:00 amRNSDeferred Annual Bonus Scheme
1st Jun 20167:00 amRNSNew appointment adds clinical expertise to Board
23rd May 20167:00 amRNSPreliminary results for year ended 31 January 2016
20th Apr 20167:00 amRNSNotice of Preliminary Results
14th Apr 20167:00 amRNSChange of Registered Office
24th Mar 20164:40 pmRNSSecond Price Monitoring Extn
24th Mar 20164:35 pmRNSPrice Monitoring Extension
11th Mar 20163:02 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Mar 20167:00 amRNS510k market clearance granted for SurgiPureT XD
9th Mar 20167:00 amRNSFurther Medicare Coverage for DermaPure®
11th Feb 20167:00 amRNSVP, Orthopaedic, Inc. North America appointed
3rd Feb 20167:00 amRNSDermaPure to be Showcased in Nine Posters at SAWC
26th Jan 201612:21 pmRNSJoint Venture Agreement
25th Jan 20167:00 amRNSHardman & Co Research Report
20th Jan 20167:00 amRNSDermaPure® breaks through $1m sales mark
19th Jan 20167:00 amRNSAppointment of Non-Executive Director
18th Jan 20167:00 amRNSOrthoPureT XM clinical trial enrolment completed
23rd Dec 201512:40 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
4th Dec 20157:00 amRNSOrthoPureT XT implants successfully undertaken
5th Nov 20154:42 pmRNSIssue of equity and total voting rights
26th Oct 20157:00 amRNSIssue of equity and total voting rights
23rd Oct 20157:49 amRNSNon-Executive Director Share Purchase
14th Oct 20154:09 pmRNSEdison initiates coverage of Tissue Regenix
12th Oct 20157:00 amRNSInterim Results
4th Sep 201510:11 amRNSNotice of Interim Results and Capital Markets Day
30th Jul 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
22nd Jul 20157:00 amRNSAdditional US regional distribution agreement
26th Jun 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure®
12th Jun 201512:43 pmRNSResult of AGM
1st Jun 20159:17 amRNSDermaPure saves 18 year old's leg from frost bite
21st May 20159:51 amRNSHolding(s) in Company
20th May 20157:00 amRNSEmployee SAYE Share Plan
12th May 20157:00 amRNSDeferred Annual Bonus Award
11th May 20157:00 amRNSFinal Results
11th May 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
5th May 20157:02 amRNSUS regional distribution agreement signed
1st May 20154:01 pmRNSHolding(s) in Company
29th Apr 20157:01 amRNSDermaPure US Clinical data to be presented at SAWC
28th Apr 20157:00 amRNSOrthoPureT XT (Tendon) UK Clinical Trial Approval
9th Mar 20152:05 pmRNSNotice of Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.